National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Lisdexamfetamine dimesylate (Tyvense®) for Attention Deficit Hyperactivity Disorder in children aged 6 years and over when response to previous methylphenidate treatment is considered clinically inadequate.

Rapid Review

Commenced Completed Outcome
09/02/2013 28/02/2013 Full Pharmacoeconomic Assessment Not Recommended